Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Tealwood Asset Management Inc. expanded its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 37.4%. After the purchase of 5,874 shares, the fund now owns 21,563 shares of the company’s stock, translating to an investment worth $1,185,000.

Three words best describe the future of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): valuation, growth, and pipeline. With the U.S. healthcare system in the limelight, particularly due to it being the most expensive system, the company’s position remains fairly unaffected since it generates merely 34% of revenues from this market.

Regarding the third characteristic, the pipeline, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has several key candidates to support the bullish stance. If we consider Palynziq, the candidate has the largest addressable market and is already authorized for commercialization in adults. According to some estimates, 1 in 10,000 to 15,000 people have phenylketonuria (PKU) worldwide, with Mordor Intelligence expecting a 9.38% CAGR between 2025 and 2030 for the drug.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), headquartered in San Rafael, California, is a biotechnology company providing solutions for serious and rare diseases and medical conditions. Incepted in 1996, the company is committed to changing the lives of many.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.